Drug · DIN 02475774
JULUCA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 4, 2018; first marketed June 4, 2018.
- Drug Identification Number (DIN)
- 02475774
- Company (DIN owner)
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Dolutegravir and rilpivirine J05AR21
- Class
- Human
- Record last updated
- November 21, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) | 50 MG | |
| RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) | 25 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 18, 2018: NOC 20876New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “juluca”. A notice may cover another product or only some lots: read it to see what it covers.
- TIVICAY, TRIUMEQ and JULUCA (dolutegravir containing medicines) – Possible Risk of Neural Tube DefectsJune 7, 2018 · Drugs · Product safety